Biotech

Seres Lays Off 30% of Staff, CSO Leaves After Pipeline Review

Seres Therapeutics was one of the first microbiome companies to form, back in 2010. And the Flagship Pioneering company was the first to go public. But today, faced with the challenges of developing a fundamentally different kind of therapeutic—consortia of human microbes—the company said it is axing 30 percent of its staff (around 30 employees and contractors), and that David Cook, its chief scientific officer, will be replaced by Matthew Henn, who was head of discovery and microbiome R&D. The layoffs will be in research, manufacturing and administration, and Cook will act as a consultant.

In a prepared statement,… Read more »

https://xconomy.com/boston/2019/02/07/seres-lays-off-30-of-staff-cso-leaves-after-pipeline-review/

Advertisements
READ  Voyager Therapeutics, AbbVie Add Parkinson’s to Gene Therapy Pact

Leave a Reply